Tissue Regenix Group (FRA:LSW) Moat Score: 0/10 (As of Jun. 29, 2026)


FRA:LSW Tissue Regenix Group PLC FRA:LSW
10 GF Score
Price €0.07
GF Value €0.84
! 5 Warning Signs
View Full Analysis

What is Tissue Regenix Group Moat Score?

Tissue Regenix Group has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Tissue Regenix Group has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Tissue Regenix Group might have No Moat - No discernible moat.

Tissue Regenix Group  (FRA:LSW) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Tissue Regenix Group Moat Score Related Terms

FRA:LSW
10GF Score
Tissue Regenix Group PLC FRA:LSW
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?

Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued. The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.

Key valuation signals for FRA:LSW:

  • Moat Score: 0
  • GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score

Get the complete analysis for FRA:LSW

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.84
GF Value